Is peptide receptor radionuclide therapy an option after liver transplantation in progressive metastatic neuroendocrine tumors?

被引：0
|
作者：
Kulkarni, Harshad [1 ]
Kaemmerer, Daniel [2 ]
Hoersch, Dieter [3 ]
Hommann, Merten [2 ]
Baum, Richard [1 ]
机构：
[1] Zent Klin, Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
[2] Zent Klin, Gen & Visceral Surg, Bad Berka, Germany
[3] Zent Klin, Internal Med Gastroenterol & Endocrinol, Bad Berka, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1177
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors
    Alayli, Adam
    Ngo, Hoang
    Sikaria, Dhiraj
    Ahmed, Altan
    Salloum, Elias
    Strosberg, Jonathan R.
    Al-Toubah, Taymeyah E.
    Kis, Bela
    Haider, Mintallah
    El-Haddad, Ghassan
    CANCERS, 2024, 16 (15)
  • [32] The use of peptide receptor radionuclide therapy in patients with metastatic low-grade neuroendocrine tumors.
    Naraev, Boris
    Sharma, Nancy
    Engelman, Eric Steven
    Bushnell, David L.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [33] Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Metastatic Low Grade Neuroendocrine Tumors (mNETs)
    Naraev, Boris G.
    Sharma, Nancy
    Engelman, Eric S.
    Bushnell, David L., Jr.
    O'Dorisio, Thomas M.
    Halfdanarson, Thorvardur R.
    PANCREAS, 2012, 41 (02) : 347 - 348
  • [34] Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
    Baum, Richard P.
    Wang, Peipei
    Jakobsson, Vivianne
    Zhao, Tianzhi
    Schuchardt, Christiane
    Khong, Pek-Lan
    Zhang, Jingjing
    THERANOSTICS, 2024, 14 (01): : 133 - 142
  • [35] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs) in a United States (US) Population
    Katona, Bryson W.
    Riff, Brian P.
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita J.
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    GASTROENTEROLOGY, 2016, 150 (04) : S208 - S209
  • [36] Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
    Santo, Giulia
    Di Santo, Gianpaolo
    Virgolini, Irene
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 557 - 569
  • [37] MYELOTOXICITY OF PEPTIDE RECEPTOR RADIONUCLIDE THERAPY OF NEUROENDOCRINE TUMORS: A DECADE OF EXPERIENCE
    Kesavan, M.
    Turner, J. H.
    HAEMATOLOGICA, 2016, 101 : 776 - 777
  • [38] Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors
    Yordanova, Anna
    Ahrens, Harriet
    Feldmann, Georg
    Brossart, Peter
    Gaertner, Florian C.
    Fottner, Christian
    Weber, Matthias M.
    Ahmadzadehfar, Hojjat
    Schreckenberger, Mathias
    Miederer, Matthias
    Essler, Markus
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (05) : E329 - E335
  • [39] Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience
    Kesavan, Murali
    Turner, J. Harvey
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2016, 31 (06) : 189 - 198
  • [40] SSTR-positive neuroendocrine tumors: peptide receptor radionuclide therapy
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 : S66 - S69
12345